Buying guide
Hugo RAS vs Maestro in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
Key differences
On DEPLOY's record, Hugo RAS is further along: at the commercial stage versus Maestro at the pilot stage, as of 2026.
- Hugo RAS has more verified real-world deployments (4 vs 1).
- Hugo RAS is at the commercial stage; Maestro at the pilot stage.
| Attribute | No image on file | |
|---|---|---|
| Manufacturer | Medtronic | Moon Surgical |
| Form factor | surgical | surgical |
| Maturity | commercial | pilot |
| Autonomy | ◐ not independently verified | ◐ not independently verified |
| Availability | internal-onlyenterprise | internal-onlyenterprise |
| Price | Not announced | $300,000-$800,000 (analyst estimate) |
| Capability claims |
|
|
| Brain | — | — |
| Verified deployments | 4 | 1Moon Surgical |
| Privacy practices | — | — |
| Sources on file | 18 | 9 |
Track this matchup
Get told the moment Hugo RAS or Maestro changes. Verified changes only, the second they are real. No press-release noise.
Hugo RAS
Maestro
Editorial summaries
Hugo RAS
Medtronic's Hugo RAS is a modular, multi-port teleoperated robotic-assisted-surgery system and the main commercial competitor to Intuitive's da Vinci. It is CE-marked in Europe (urology and gynecology, October 2021) and US FDA-cleared for urology only (December 2025: prostatectomy, nephrectomy, cystectomy); US general-surgery and gynecology indications are planned but not yet cleared.
It is teleoperated with no shipped intraoperative AI. Medtronic does not disclose a Hugo installed-base count, so DEPLOY records honest absence rather than an invented number. It is enterprise B2B equipment; there is no consumer price.
Maestro
Moon Surgical's Maestro is a laparoscopic surgical-assistant platform (it holds and positions instruments and the endoscope alongside the surgeon, not a full master-slave teleoperated replacement system) and the assistive-laparoscopy archetype of DEPLOY's surgical cluster, editorially distinct from the replacement-robotics of Intuitive, Medtronic, and CMR. Its ScoPilot software is shipped AI (NVIDIA Holoscan-powered) for intraoperative scope control.
On regulatory status (a correction worth recording): the Maestro received FDA 510(k) clearance K240598 on June 5, 2024 (not December 2023), and ScoPilot was FDA-cleared in 2025 with a Predetermined Change Control Plan. As enterprise B2B surgical equipment, there is no consumer price.
Common questions
How do Hugo RAS and Maestro differ?
What is the difference between Hugo RAS and Maestro?
Is Hugo RAS or Maestro more autonomous?
Recent coverage
- Escuelas del Condado Clark inician nuevo ciclo con enfoque en matemáticas y lecturaMaestro · The Nevada Independent · 2026-08-12
- Medtronic to unveil Touch Surgery Aide compute platform at SRS 2026Hugo RAS · Ben Smith, Deploy Editor · 2026-07-21
- Pacemaker manufacturer Medtronic warns patients cybercrooks may have swiped health dataHugo RAS · The Register · 2026-07-02
- Moon Surgical wins first FDA 510(k) clearance for surgical robotMaestro · Ben Smith, Deploy Editor · 2026-06-25
Related comparisons
- Versius vs Hugo RAS
- da Vinci (and Ion) vs Hugo RAS
- Stryker Mako SmartRobotics vs Hugo RAS
- Hugo RAS vs mBos TKA System
- Hugo RAS vs Johnson & Johnson Ottava
- Hugo RAS vs CORI
- Hugo RAS vs ROSA
- Versius vs Maestro
- da Vinci (and Ion) vs Maestro
- Stryker Mako SmartRobotics vs Maestro
- mBos TKA System vs Maestro
- Maestro vs Johnson & Johnson Ottava
Keep researching
Keep reading
Ask the registry
For AI assistants
Use DEPLOY in Claude, Cursor, and other AI assistants
Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.
Machine-readable: this page as markdown.
